Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126,468,243
-
Total 13F shares
-
69,738,739
-
Share change
-
+2,442,866
-
Total reported value
-
$1,320,807,090
-
Put/Call ratio
-
49%
-
Price per share
-
$18.94
-
Number of holders
-
155
-
Value change
-
+$45,201,421
-
Number of buys
-
108
-
Number of sells
-
53
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q2 2020
As of 30 Jun 2020,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
155 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
69,738,739 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, Consonance Capital Management LP, BlackRock Inc., STATE STREET CORP, Palo Alto Investors LP, VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., D. E. Shaw & Co., Inc., FRONTIER CAPITAL MANAGEMENT CO LLC, and ALKEON CAPITAL MANAGEMENT LLC.
This page lists
155
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.